DF/HCC Program Affiliation

Member, Translational Pharmacology and Early Therapeutic Trials Program
Member, Invasion, Metastasis, and Angiogenesis Program
Member, Breast Cancer Program

Research Abstract

The long term goal of our research is to understand the fundamental nature of vascular and interstitial barriers in human and rodent tumors, to overcome them or to exploit them for cancer detection and treatment. Quantitative understanding of pathophysiological phenomena in solid tumors is developed using five unique yet complementary approaches in our research: 1) a macroscopic approach using tissue-isolated tumors to monitor arterial and venous blood in rodent and human tumors; 2) a microscopic approach to directly visualize the events in the tumor microcirculation; 3) in vitro characterization of deformability, permeability, and adhesion of cells; 4) molecular biology techniques including development of transgenic cell lines and animals; and 5) mathematical modeling to integrate existing data and to guide new clinical and experimental studies. These five approaches are intertwined in six interdisciplinary projects: 1) tumor blood flow; 2) metabolic microenvironment; 3) transvascular transport; 4) interstitial transport; 5) cell transport; and 6) mathematical modeling.

Publications

• RK Jain. Taming vessels to treat cancer. Sci Am 2008 Jan 1; 1(298):56-63
  PMID: 0
• Duda DG, Batchelor TT, Willett CG, Jain RK. VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol Med 2007 Apr 24;
  PMID: 17462954
• Duda DG, Cohen KS, Scadden DT, Jain RK. A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood. Nat Protoc 2007; 2(4):805-10
  PMID: 17446880
• Wang ZZ, Au P, Chen T, Shao Y, Daheron LM, Bai H, Arzigian M, Fukumura D, Jain RK, Scadden DT. Endothelial cells derived from human embryonic stem cells form durable blood vessels in vivo. Nat Biotechnol 2007 Mar; 25(3):317-8
  PMID: 17322871
• Lawenda BD, Smith DE, Xu L, Niemierko A, Silverstein JR, Boucher Y, Kashiwagi S, Held KD, Jain RK, Loeffler JS, Eisenberg DM, Blumberg JB. Do the dietary supplements epigallocatechin gallate or vitamin e cause a radiomodifying response on tumors in vivo? A pilot study with murine breast carcinoma. J Soc Integr Oncol 2007 Winter; 5(1):11-7
  PMID: 17309809
• Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007 Jan; 11(1):83-95
  PMID: 17222792
• Brown E, McKee T, diTomaso E, Pluen A, Seed B, Boucher Y, Jain RK. Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat Med 2003 Jun; 9(6):796-800
  PMID: 12754503
• Jain RK, Munn LL, Fukumura D. Dissecting tumour pathophysiology using intravital microscopy. Nat Rev Cancer 2002 Apr; 2(4):266-76
  PMID: 12001988
• Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 2002 Mar 21; 416(6878):279-80
  PMID: 11907566
• Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001 Sep; 7(9):987-9
  PMID: 11533692